4,901 trials
Healthy Volunteers
Primary: Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 38702.8145; 39359.7493; 39270.1707 h·μg/mL
Infection, Human Immunodeficiency Virus
Primary: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity [AUC (0-Inf)] of Plasma DTG and 3TC in the Fasted State: Part 1 — 43.1456; 54.8793; 12.3337…
Healthy
Primary: Area Under the Concentration-time Curve of the BI 695501 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 2740; 2390; 2050…
Hypertension
Primary: Number of Participants Who Experienced One or More Adverse Events — 2; 3; 5; 2 Participants
Migraines
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t)…
Dense Deposit Disease · Membranoproliferative Glomerulonephritis
Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants
Healthy
Primary: Cmax of Narlaprevir — 2130.2742; 2172.233; 2946.131; 2880.612 ng/ml
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0 Participants
Japanese Healthy Adult Male Participants
Primary: Number of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) — 1; 0; 2; 1 Participants
Healthy Volunteers · Renal Impairment
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Dosing to Last Measurable Concentration (AUC0-last) of MK-6183 — 87.6; 114.8; 97.5; 228.0 ug*hr/mL
Glioblastoma
Primary: Number of Patients With Investigator Defined Dose Limiting Toxicities (DLT) During the RT Phase — 1; 0; 2; 0 Participants
Renal Impairment · Type 2 Diabetes Mellitus
Primary: Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 Extrapolated to Infinite Time (AUCinf) — 1199; 1908; 2075; 1895 ng•hr/mL
HIV-1 Infection
Primary: Percentage Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load — -1.52; -1.41; -0.15 Percentage change — p=<0.001